A proof of concept for targeting the delivery of interferons was implicated by a study that showed IFN-γ gene delivery can effectively treat airway hyperresponsiveness and eosinophilia in mice through both intravenous and intratracheal delivery methods [63]. This evidence concerns the gene IFNG and airway hyperresponsiveness.